Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kyverna Therapeutics Q2 EPS $(0.97) Beats $(1.04) Estimate

Author: Benzinga Newsdesk | August 12, 2025 03:21pm
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.04) by 7.09 percent. This is a 44.78 percent decrease over losses of $(0.67) per share from the same period last year.

Posted In: KYTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist